Skip to content
Subscriber Only

Regeneron, Lilly Reveal Positive Results for Antibody Combos

  • Regeneron treatment prevented all Covid symptoms in analysis
  • Therapies could be needed amid slow vaccinations, new strains
Regeneron Pharmaceuticals Inc. signage is displayed outside their headquarters in Tarrytown, N.Y., U.S., on June 12, 2020. Regeneron Pharmaceuticals Inc. said it had begun human trials of a new antibody cocktail for Covid-19, part of an ambitious clinical-testing plan that could lead to a new treatment option by the end of summer if all goes well.
Photographer: Michael Nagle/Bloomberg
Updated on

Regeneron Pharmaceuticals Inc. and Eli Lilly and Co. each reported positive results from Covid-19 antibody drug combinations Tuesday, as both companies seek to expand use of their therapies and ensure effectiveness against new strains.

Regeneron said its antibody cocktail reduced Covid-19 cases by half and prevented all symptoms in people at high risk of catching the coronavirus. A combination of two antibodies that Lilly’s advancing to combat new variants cut the chances of hospitalizations and deaths by 70% in high-risk patients.